Laurus Labs Limited vs Parabolic Drugs Ltd

A side-by-side comparison of Laurus Labs Limited (LAURUSLABS) and Parabolic Drugs Ltd (PARABDRUGS) — valuation, profitability, growth, and financial health — to help you judge which is the stronger buy today.

The verdict

On the numbers, Laurus Labs Limited leads LAURUSLABS vs PARABDRUGS on 9 of 14 metrics (2 undecided). See the breakdown below — the right pick still depends on your goals (value vs growth, risk appetite).

  • Valuation22
  • Profitability40
  • Growth· not comparable—
  • Size & financial health31

Valuation

Even

How expensive each stock is relative to its earnings and book value. Lower usually means cheaper.

125.08
P/E ratio
0.00
19.74
P/B ratio
0.00
0.10%
Dividend yield
0.00%
₹16.47
EPS
₹-4.63

Profitability

LAURUSLABS takes 4/4

How efficiently each company turns capital and sales into profit. Higher is better.

16.77%
Return on equity
0.00%
17.58%
Return on capital
0.00%
26.09%
EBITDA margin
0.00%
13.07%
Net margin
0.00%

Growth

Three-year compounded growth. Faster-growing businesses can justify a higher valuation.

4.09%
Revenue CAGR (3Y) even
—
3.91%
Profit CAGR (3Y) even
—

Size & financial health

LAURUSLABS takes 3/4

Scale and balance-sheet strength. Bigger revenue/profit and lower debt are generally safer.

₹1.11L Cr
Market cap
₹0 Cr
₹6,813 Cr
Revenue
₹0 Cr
₹890 Cr
Net profit
₹-29 Cr
0.45
Debt / equity
0.00
Laurus Labs Limited
  • + []
  • − ["Stock is trading at 20.99 times its book value", "The company has delivered a poor sales growth of 7.2% over past five years.", "The company has delivered a poor profit growth of -2.0% over past five years."]
Parabolic Drugs Ltd
  • + ["Company has reduced debt."]
  • − ["Company has low interest coverage ratio."]
Laurus Labs Limited full analysis Parabolic Drugs Ltd full analysis

This comparison is for informational purposes only and is not investment advice. Please consult a SEBI-registered advisor before investing.